110 results about "Apolipoproteins A" patented technology

The invention relates to genetic approaches to supply nucleotide sequences encoding modified forms of the native forms of apolipoprotein A-I (ApoA-I): mature ApoA-I, preproApoA-I and proApoA-I; including native ApoA-I modified to contain ApoA-I agonists, peptides which mimic the activity of ApoA-I; ApoA-I superagonists, peptides which exceed the activity of native ApoA-I; and modified native ApoA-I having one or more amphipathic helices replaced by the nucleotide sequences of one or more ApoA-I agonists; for the treatment of disorders associated with dyslipoproteinemia, including cardiovascular disease, atherosclerosis, restenosis, hyperlipidemia, and other disorders such as septic shock.

The present invention provides peptidomimetics derived from Apolipoprotein A-I, which is useful for beneficially influencing lipid parameters and/or plasma cholesterol levels. The invention also provides pharmaceutical compositions and methods of treatment for elevated levels of plasma cholesterol.

The invention discloses a stable liquid lipid calibrator which comprises 20-200mmol/L of buffer liquid, 2-10% (w/v) of protein stabilizer, 110-200mmol/L of electrolyte NaC, 5-100mmol/L of anti-oxidation synergist, 10-100g/L of sugar stabilizer, 0.09% (w/v) of preservative, 0.02-100mmpl/L of antioxidant, 0.1-5mmol/L of protease inhibitor, 2.0-3.0g/L of apolipoprotein A-I and 2-2.5g/L of apolipoprotein B. By adopting the stable liquid lipid calibrator, the stability of the apolipoprotein A-I and the apolipoprotein B is effectively improved, the apolipoprotein A-I and the apolipoprotein B can be stably frozen at 2-8 DEG C for one year and are relatively convenient and efficient to use and preserve, and the accuracy in measuring the contents of the apolipoprotein A-I and apolipoprotein B in a sample is improved.

An ophthalmic composition is provided which is capable of enhancing a barrier function of a lipid layer that constitutes a tear film, for thereby restricting and curing corneal disorders such as dry eye. It is also an object of the invention to provide the ophthalmic composition with anti-inflammatory and antimicrobial effects for thereby advantageously preventing and easing corneal/conjunctival disorders such as keratoconjunctivitis. In the present invention, apolipoprotein A-1 is included, as an active ingredient, in the ophthalmic composition.

The invention relates to a method of diagnosis of Huntington's Disease in a diagnostic sample of a valid body tissue taken from a human subject, which comprises detecting an altered concentration of a protein in the diagnostic sample, compared with a sample of a control human subject, the protein being selected from: Swiss Prot accession number: Protein name; P10909: Clusterin precursor; P00738: Haptoglobin precursor; P01009: Alpha-1-antitrypsin precursor; P01024: Complement C3 precursor; P01620: 1 g kappa chain V-III region; P01834: 1 g kappa chain C region P01842: 1 g lambda chain C regions; P01857: 1 g gamma-1 chain C region; P01859: Ig gamma-2 chain C region; P01876: 1 g alpha-1 chain C region P02647: Apolipoprotein A-I precursor; P02649: Apolipoprotein E precursor; P02652: Apolipoprotein A-II precursor; P02655: Apolipoprotein C-II precursor; P02656: Apolipoprotein C-II precursor P02671: Fibrinogen alpha/alpha-E chain precursor; P02763: Alpha-1-acid glycoprotein 1 precursor; P02766: Transthyretin precursor; P02768: Serum albumin precursor; P02787: Serotransferrin precursor; P04196: Histidine-rich glycoprotein precursor; P06727: Apolipoprotein A-IV precursor; P19652: Alpha-1-acid glycoprotein 2 precursor; P68871/P02042: Hemoglobin beta chain/Hemoglobin delta chain; P60709: Beta actin.

A method including advancing a delivery device through a lumen of a blood vessel to a particular region in the blood vessel; and introducing a composition including a sustained-release carrier and an apolipoprotein A-I (apo A-I) synthetic mimetic peptide into a wall of the blood vessel at the particular region or a perivascular site, wherein the peptide has a property that renders the peptide effective in reverse cholesterol transport. A composition including an apolipoprotein A-I (apo A-I) synthetic peptide, or combination of an apo A-I synthetic mimetic peptide and an Acyl CoA cholesterol: acyltransferase (ACAT) inhibitor in a form suitable for delivery into a blood vessel, the peptide including an amino acid sequence in an order reverse to an order of various apo A-I mimetic peptides, or endogenous apo A-I analogs, or a chimera of helix 1 and helix 9 of endogenous apo A-I.

The invention relates to a method for assessing the risk of a cardiovascular disease and/or for diagnosing dyslipidemia in a patient, said method comprising: a) isolating in a blood sample obtained from said patient the high density lipoprotein (HDL) fraction or a subfraction thereof; and b) measuring in said HDL fraction or subfraction thereof the concentration of one or more biomarkers selected from the group consisting of Sphingosine-1-Phosphate (S1P), sphingomyelin (SM) and Apolipoprotein A-I (apoA-1).

The invention discloses a method for preparing high-purity ApoA-I (Apolipoprotein A-I) from a plasma fraction IV through purification, comprising the following steps of: dissolving the participates of the plasma fraction IV, centrifuging to remove diatomite and impurities, and collecting a supernate; adding sodium chloride to the supernate so that ApoA-I protein is coagulated and separated out, and centrifuging to obtain an ApoA-I precipitate; redissolving the precipitate and filtrating; and enabling the filtrate to be sequentially subjected to anion column chromatography and hydrophobic column chromatography and separating to obtain a high-purity ApoA-I solution. The ApoA-I prepared by adopting the process disclosed by the invention has high purity capable of reaching more than 95 percent and the ApoA-I yield capable of reaching 70 percent and is safe and convenient to operate, easy to realize process amplification and very suitable for industrial production.

Provided are peptides, compositions thereof, and methods for treating or preventing dyslipidemia, a cardiovascular disease, endothelial dysfunction, a macrovascular disorder, or a microvascular disorder.

The invention discloses a VHH chain of a single-domain antibody for apolipoprotein A1. The VHH chain comprises a frame region FR and a complementary determining region CDR. The invention discloses amino acid sequences of the frame region FR selected from the following group of FR and the amino acid sequences of the complementary determining region CDR. The invention also discloses two types of single-domain antibodies for the apolipoprotein A1, also discloses two types of DNA molecules for coding the VHH chain of the single-domain antibody for the apolipoprotein A1 mentioned in the invention or the single-domain antibody for the apolipoprotein A1 mentioned in the invention, also discloses a host cell for expressing the single-domain antibody for the apolipoprotein A1, and also discloses the application of the single-domain antibody for the apolipoprotein A in detection of the apolipoprotein A1. Through the gene sequences and the host cell of the single-domain antibody disclosed by the invention, the single-domain antibody can be efficiently expressed in colon bacillus and applied in research and development of an apolipoprotein A1 detection reagent.

The present invention features a non-invasive system and method for delivering apolipoprotein, amphipathic compounds, and the like into the blood stream using pulmonary delivering. Apolipoprotein, amphipathic compounds, and the like is suspended in a solvent, preferably a saline solution. Next, the soluation is nebulized to form a plurality of droplets sized to reach the periphery of the lung. Once proximate the lung, the apolipoprotein, amphipathic compounds, and the like is dissolved through the lung interface and into the serum. Due to its physical and chemical properties, apolipoprotein A-I is effectively absorbed into the serum through the lung. The present invention can be used for the treatment of cardiovascular disease as well Alzheimer's Disease and other.

A first method of purifying apolipoprotein A-1 includes mixing plasma fraction IV with a 1-8 M urea solution to form a pretreatment solution; loading the pretreatment solution to a first anion chromatography column, and then eluting to obtain an apoA-1 protein solution; and loading the apoA-1 protein solution to a second anion chromatography column, and eluting to obtain pure apoA-1 protein. A second method includes dissolving plasma fraction IV in a buffer to produce a pretreatment solution; adding NaCl to the pretreatment solution and cooling it to form apoA-1 precipitate; collecting and reconstituting the apoA-1 precipitate; loading the reconstituted apoA-1 to an anion exchange column; and eluting apoA-1 from the column.